Ignite Creation Date:
2025-12-24 @ 7:51 PM
Ignite Modification Date:
2026-03-01 @ 12:04 PM
Study NCT ID:
NCT02787304
Status:
TERMINATED
Last Update Posted:
2019-11-25
First Post:
2016-05-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
Sponsor:
Mirum Pharmaceuticals, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Non-Alcoholic Steatohepatitis | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | NAFLD activity score | View |
| None | ASBTi | View |
| None | MRI PDFF | View |
| None | NAS | View |
| None | NAFLD | View |
| None | liver disease | View |
| None | ASBT | View |
| None | MRI proton density fat fraction | View |
| None | nonalcoholic steatohepatitis | View |
| None | apical sodium dependent bile acid transporter inhibitor | View |
| None | fatty liver | View |
| None | NASH | View |